NeuroSense ALS Drug PrimeC Shows Long-Term Safety in Phase 2a
Ticker: NRSNW · Form: 6-K · Filed: Aug 20, 2025 · CIK: 1875091
| Field | Detail |
|---|---|
| Company | Neurosense Therapeutics LTD. (NRSNW) |
| Form Type | 6-K |
| Filed Date | Aug 20, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: drug-safety, clinical-trial, ALS
TL;DR
NeuroSense's ALS drug PrimeC is looking good long-term: 20% of patients on it for 5.5+ years, no new safety issues.
AI Summary
NeuroSense Therapeutics Ltd. reported on August 20, 2025, that approximately 20% of ALS patients from their Phase 2a study, who are continuing on compassionate use, have remained on PrimeC for over 5.5 years. These patients have lived with ALS for more than 7 years, and the treatment has remained well-tolerated with no new safety signals observed.
Why It Matters
This long-term safety data for PrimeC in ALS patients could support its potential for extended use and further clinical development, offering hope for chronic neurodegenerative disease treatment.
Risk Assessment
Risk Level: medium — While long-term safety is positive, the data is from a Phase 2a study and a small percentage of patients, and does not yet confirm efficacy.
Key Numbers
- 20% — ALS Patients on PrimeC (Percentage of Phase 2a patients continuing treatment for over 5.5 years.)
- 5.5 years — Long-Term Treatment Duration (Minimum duration of PrimeC treatment for a subset of patients.)
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Filer of the report
- PrimeC (drug) — Investigational drug for ALS
- August 20, 2025 (date) — Date of the report and data snapshot
- 5.5 years (duration) — Duration of PrimeC treatment for some patients
- 7 years (duration) — Total duration of ALS for some patients
FAQ
What is the primary purpose of this 6-K filing?
This 6-K filing reports on the long-term safety data of NeuroSense Therapeutics Ltd.'s drug PrimeC in patients with ALS from their Phase 2a study.
How long have some ALS patients been treated with PrimeC?
Approximately 20% of ALS patients from the Company's Phase 2a study have remained on PrimeC for more than 5.5 years, with some having lived with ALS for over 7 years.
Have any new safety concerns been identified with PrimeC during this extended treatment period?
No, the filing states that across these multi-year exposures, treatment remains well tolerated, with no new safety signals observed to date.
What is the status of the study mentioned in the filing?
The data pertains to patients from the Company's Phase 2a study, with some continuing treatment under compassionate use.
What is the ticker symbol for NeuroSense Therapeutics Ltd.?
The filing does not explicitly state the ticker symbol, but the SEC file number is 001-41084.
Filing Stats: 268 words · 1 min read · ~1 pages · Grade level 11.1 · Accepted 2025-08-20 09:31:02
Filing Documents
- ea0254016-6k_neurosense.htm (6-K) — 9KB
- 0001213900-25-078783.txt ( ) — 10KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: August 20, 2025 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Officer 2